This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
by Zacks Equity Research
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.
Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs
by Zacks Equity Research
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
by Zacks Equity Research
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
by Zacks Equity Research
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 0% and 3.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -20.00% and -10.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
by Zacks Equity Research
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 27.27% and 18.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Pharmaceuticals (RIGL) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 2100.00% and 102.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Company News for Apr 14, 2021
by Zacks Equity Research
Companies in the news are: MFNC, NVCR, RIGL, VTVT
Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals (RIGL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 4.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 23.08% and 12.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?